Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
Lai YR, Cappellini MD, Aydinok Y, Porter J, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Liu R, Izquierdo M, Lasher J, Govindaraju S, Taher A. Lai YR, et al. Among authors: lasher j. Am J Hematol. 2022 Aug;97(8):E281-E284. doi: 10.1002/ajh.26592. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560253 Free article. No abstract available.
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X, Shen G, Jiang J, Liu H, Hu K, Darstein C, Lasher J, Hu P. Chen X, et al. Among authors: lasher j. Clin Ther. 2014 Aug 1;36(8):1196-210. doi: 10.1016/j.clinthera.2014.06.006. Epub 2014 Jul 8. Clin Ther. 2014. PMID: 25012727 Free article. Clinical Trial.
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N. Petersenn S, et al. Among authors: lasher j. Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24. Clin Ther. 2012. PMID: 22364824 Clinical Trial.
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. Among authors: lasher j. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.
Proceedings of the 15th Annual UT-KBRIN Bioinformatics Summit 2016 : Cadiz, KY, USA. 8-10 April 2016.
Rouchka EC, Chariker JH, Harrison BJ, Park JW, Cao X, Pounds S, Raimondi S, Downing J, Ribeiro R, Rubnitz J, Lamba J, Daigle BJ Jr, Burgess D, Gehrlich S, Carmen JC, Johnson N, Emani C, Gehrlich S, Burgess D, Carmen JC, De Silva K, Heaton MP, Kalbfleisch TS, Viangteeravat T, Mudunuri R, Ajayi O, Şen F, Huang EY, Mohebbi M, Florian L, Jackson DJ, Naber JF, Sabbir AKM, Ellingson SR, Lu Y, Phillips CA, Langston MA, Sevakula RK, Thirukovalluru R, Verma NK, Cui Y, Sayed M, Park JW, Wang J, Liu Q, Shyr Y, Zhang X, Ellingson SR, Prodduturi N, Oliver GR, Grill D, Na J, Eckel-Passow J, Klee EW, Goodin MM, Farman M, Inocencio H, Jang C, Jaromczyk JW, Moore N, Sovacool K, Dent L, Izban M, Mandape S, Sakhare S, Pratap S, Marshall D, DePriest MS, MacLeod JN, Kalbfleisch TS, Emani C, Adam H, Blandford E, Campbell J, Castlen J, Dixon B, Gilbert G, Hall A, Kreisle P, Lasher J, Oakes B, Speer A, Valentine M, Nagisetty NSVR, Jose R, Viangteeravat T, Rooney R, Hains D. Rouchka EC, et al. Among authors: lasher j. BMC Bioinformatics. 2016 Aug 19;17(Suppl 10):297. doi: 10.1186/s12859-016-1154-y. BMC Bioinformatics. 2016. PMID: 28166713 Free PMC article.
36 results